Literature DB >> 26081142

The Role of TDP-43 in Alzheimer's Disease.

Xiao-Long Chang1, Meng-Shan Tan2, Lan Tan3,4, Jin-Tai Yu5,6.   

Abstract

The transactive response DNA binding protein (TDP-43) has long been characterized as a main hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U, also known as FTLD-TDP). Several studies have indicated TDP-43 deposits in Alzheimer's disease (AD) brains and have robust connection with AD clinical phenotype. FTLD-U, which was symptomatically connected with AD, may be predictable for the comprehension of the role TDP-43 in AD. TDP-43 may contribute to AD through both β-amyloid (Aβ)-dependent and Aβ-independent pathways. In this article, we summarize the latest studies concerning the role of TDP-43 in AD and explore TDP-43 modulation as a potential therapeutic strategy for AD. However, to date, little of pieces of the research on TDP-43 have been performed to investigate the role in AD; more investigations need to be confirmed in the future.

Entities:  

Keywords:  Alzheimer’s disease; Aβ; Pathogenesis; TDP-43; Tau; Therapy

Mesh:

Substances:

Year:  2015        PMID: 26081142     DOI: 10.1007/s12035-015-9264-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  91 in total

1.  The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects.

Authors:  Marie Y Davis; C Dirk Keene; Suman Jayadev; Thomas Bird
Journal:  J Huntingtons Dis       Date:  2014

2.  The seeds of neurodegeneration: prion-like spreading in ALS.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

Review 3.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 4.  Alzheimer's disease.

Authors:  Vanessa J De-Paula; Marcia Radanovic; Breno S Diniz; Orestes V Forlenza
Journal:  Subcell Biochem       Date:  2012

Review 5.  Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease.

Authors:  Jerry R Colca; Douglas L Feinstein
Journal:  Adv Pharmacol       Date:  2012

6.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

7.  Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration.

Authors:  Penelope G Foulds; Yvonne Davidson; Manjari Mishra; David J Hobson; Kirsty M Humphreys; Mark Taylor; Nancy Johnson; Sandra Weintraub; Haruhiko Akiyama; Tetsuaki Arai; Masato Hasegawa; Eileen H Bigio; Fiona E Benson; David Allsop; David M A Mann
Journal:  Acta Neuropathol       Date:  2009-10-13       Impact factor: 17.088

8.  Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients.

Authors:  Yu-Sheng Fang; Kuen-Jer Tsai; Yu-Jen Chang; Patricia Kao; Rima Woods; Pan-Hsien Kuo; Cheng-Chun Wu; Jhih-Ying Liao; Shih-Chieh Chou; Vinson Lin; Lee-Way Jin; Hanna S Yuan; Irene H Cheng; Pang-Hsien Tu; Yun-Ru Chen
Journal:  Nat Commun       Date:  2014-09-12       Impact factor: 14.919

9.  TDP-43 regulates Drosophila neuromuscular junctions growth by modulating Futsch/MAP1B levels and synaptic microtubules organization.

Authors:  Vinay K Godena; Giulia Romano; Maurizio Romano; Chiara Appocher; Raffaella Klima; Emanuele Buratti; Francisco E Baralle; Fabian Feiguin
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

10.  Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo.

Authors:  Andrea D'Ambrogio; Emanuele Buratti; Cristiana Stuani; Corrado Guarnaccia; Maurizio Romano; Youhna M Ayala; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2009-05-08       Impact factor: 16.971

View more
  28 in total

1.  The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain.

Authors:  W Michael Babinchak; Raza Haider; Benjamin K Dumm; Prottusha Sarkar; Krystyna Surewicz; Jin-Kyu Choi; Witold K Surewicz
Journal:  J Biol Chem       Date:  2019-02-27       Impact factor: 5.157

Review 2.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

3.  TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.

Authors:  Mauro Montalbano; Salome McAllen; Filippa Lo Cascio; Urmi Sengupta; Stephanie Garcia; Nemil Bhatt; Anna Ellsworth; Eric A Heidelman; Omar D Johnson; Samantha Doskocil; Rakez Kayed
Journal:  Neurobiol Dis       Date:  2020-10-14       Impact factor: 5.996

4.  Granulins modulate liquid-liquid phase separation and aggregation of the prion-like C-terminal domain of the neurodegeneration-associated protein TDP-43.

Authors:  Anukool A Bhopatkar; Vladimir N Uversky; Vijayaraghavan Rangachari
Journal:  J Biol Chem       Date:  2020-01-06       Impact factor: 5.157

5.  Environmental Enrichment Mitigates Deficits after Repetitive Mild Traumatic Brain Injury.

Authors:  Xixia Liu; Jianhua Qiu; Sasha Alcon; Jumana Hashim; William P Meehan; Rebekah Mannix
Journal:  J Neurotrauma       Date:  2017-06-08       Impact factor: 5.269

6.  Targeting TDP-43 Pathology Alleviates Cognitive and Motor Deficits Caused by Chronic Cerebral Hypoperfusion.

Authors:  Sai Sampath Thammisetty; Laurence Renaud; Vincent Picher-Martel; Yuan Cheng Weng; Frédéric Calon; Stephan Saikali; Jean-Pierre Julien; Jasna Kriz
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

7.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

Review 8.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

9.  In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

Authors:  Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

10.  Phosphorylated TDP-43 Staging of Primary Age-Related Tauopathy.

Authors:  Xiaoling Zhang; Bing Sun; Xing Wang; Hui Lu; Fangjie Shao; Annemieke J M Rozemuller; Huazheng Liang; Chong Liu; Jiadong Chen; Manli Huang; Keqing Zhu
Journal:  Neurosci Bull       Date:  2018-10-31       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.